Daiichi Sankyo is committed to addressing neglected needs in cardiovascular care, highlighting disparities in treatment and outcomes between different patient groups.
Recent studies, such as SANTORINI and ETNA-AF, have shed light on gender differences in cardiovascular treatment. Women at high cardiovascular risk are undertreated and achieve recommended LDL cholesterol (LDL-C) levels to a lesser extent than men.
The SANTORINI study found that women were less likely to achieve LDL-C goals, despite guideline recommendations being similar for both sexes. In addition, more women did not receive any cholesterol-lowering treatment compared to men.
Professor David Nanchen highlights that these disparities suggest that women are being undertreated and not receiving recommended LDL-C levels. This underscores the need for improved care to better manage cardiovascular risk in women.
Daiichi Sankyo’s studies have also explored therapeutic adherence, finding that patients who discontinue treatment are at increased risk of serious cardiovascular events. Strategies to improve adherence, such as simplifying treatment regimens and supporting patients, are needed.
Daiichi Sankyo is collaborating on studies such as SANTORINI to identify the causes of the burden of cardiovascular disease in Europe and develop solutions for people who have previously not received adequate treatment. The company aims to provide scientific evidence to support optimal treatment of cardiovascular patients and reduce disparities in care.
Source link: http://www.businesswire.com/news/home/20240831795891/es/
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
